Invasive Pulmonary Aspergillosis Clinical Trial
Official title:
Use of Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
NCT number | NCT05897294 |
Other study ID # | TFF-VE-001 |
Secondary ID | |
Status | Available |
Phase | |
First received | |
Last updated |
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks. Duration of treatment may be extended on a case-by-case basis depending on drug availability and after discussion with the Sponsor.
Status | Available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female aged 18 years or older at screening. 2. Diagnosed with pulmonary aspergillosis including Invasive Pulmonary Aspergillosis (IPA), Chronic Pulmonary Aspergillosis (CPA), Allergic Bronchopulmonary Aspergillosis (ABPA), Aspergillus tracheobronchitis and Aspergillus bronchial anastomotic infection. Pulmonary infections with voriconazole sensitive fungi other than Aspergillus such as but not limited to scedosporium and fusarium are also allowed. 3. Patient has limited or no treatment options due to documented or anticipated intolerance, toxicity, contraindications, or lack of clinical response to SOC antifungal therapy, as advocated by the relevant regional treatment guidelines. 4. The treating clinician considers that the potential advantage of using Voriconazole Inhalation Powder outweighs the potential risks. In patients with disseminated fungal infection in addition to pulmonary infection, Voriconazole Inhalation Powder must be used as add-on therapy to the current SOC. 5. The Sponsor agrees that the benefit:risk assessment is favorable for the use of Voriconazole Inhalation Powder in the patient. 6. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test (UPT) prior to first dose. Sexually active WOCBP and male patients must agree to use highly effective birth control or abstinence until 3 months after last dose. 7. Patient succeeds in meeting training criteria on the use of the dry powder inhaler (DPI) and is willing and able to perform adequate inhalation technique for treatment duration in the opinion of the treating clinician or designee. 8. Patient provides informed consent and agrees to follow the treatment regimen and safety and outcomes assessments. Exclusion Criteria: 1. Infection with fungi not responsive to voriconazole. 2. Pregnant or breastfeeding. 3. History or presence of hypersensitivity or idiosyncratic reaction to voriconazole or excipients in Voriconazole Inhalation Powder. 4. Patients with severe liver disease as defined by Child-Pugh Class C. 5. Patients who are eligible and are able to participate in a clinical trial of Voriconazole Inhalation Powder. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
TFF Pharmaceuticals, Inc. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01782131 -
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
|
Phase 3 | |
Recruiting |
NCT05138666 -
Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.
|
N/A | |
Not yet recruiting |
NCT02234739 -
Voriconazole for IPA in Chinese Patients With COPD
|
Phase 4 | |
Completed |
NCT01615809 -
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
|
Phase 2 | |
Completed |
NCT04267497 -
Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)
|
Phase 1 | |
Recruiting |
NCT05860387 -
Early Diagnosis of Invasive Lung Aspergillosis
|
||
Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
Completed |
NCT00923832 -
Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
|
N/A | |
Recruiting |
NCT05982912 -
VOC in Breath Samples for the Diagnosis of IPA
|
||
Not yet recruiting |
NCT02100761 -
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
|
N/A | |
Recruiting |
NCT00986713 -
Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
|
Phase 4 | |
Recruiting |
NCT05569824 -
LFD of Aspergillus Antigen in Paediatrics
|
||
Not yet recruiting |
NCT04848831 -
Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid
|
||
Completed |
NCT04077697 -
Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.
|
||
Completed |
NCT03672292 -
Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
|
Phase 2 | |
Recruiting |
NCT01499433 -
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
|
Phase 4 | |
Completed |
NCT01247142 -
Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis
|
N/A | |
Completed |
NCT00501098 -
Prophylaxis of Fungal Invasive Infections in Leukemia
|
Phase 2 | |
Recruiting |
NCT03748069 -
Influenza Associated Aspergillosis In-depth Investigation
|
||
Completed |
NCT02058316 -
Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
|